Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001385
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Positron Emission Tomography in Patients With Breast Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Positron Emission Tomography in Patients With Breast Cancer
Status:
COMPLETED
Status Verified Date:
1999-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective study evaluating the role of Positron Emission Tomography PET scan in breast cancer The radiopharmaceutical 18F 2-deoxyglucose will be used as both an imaging modality and to evaluate tumor metabolism in patients with breast cancer Patients with stage II stage IIIA or IIIB or stage IV breast cancer and evaluable disease in the breast andor at metastatic sites will be studied Patients will be injected intravenously with 18F2-deoxyglucose and a PET scan conducted over 90 minutes Examination of the role of PET scan in assessing the response of breast cancer to chemotherapy especially in stage II and stage III patients will be done Up to three PET scans within one year may be performed Findings by PET scan will be correlated both with those of concurrent imaging techniques x-ray CT scan MRI bone scan or mammogram and with histologic biochemical and flow cytometric information on the tumor and with findings in subsequent surgical specimens Changes in tumor glucose metabolism with treatment will be assessed by PET imaging studies and by biochemical methods when possible
Detailed Description:
This is a prospective study evaluating the role of Positron Emission Tomography PET scan in breast cancer The radiopharmaceutical 18F 2-deoxyglucose will be used as both an imaging modality and to evaluate tumor metabolism in patients with breast cancer Patients with stage II stage IIIA or IIIB or stage IV breast cancer and evaluable disease in the breast andor at metastatic sites will be studied Patients will be injected intravenously with 18F2-deoxyglucose and a PET scan conducted over 90 minutes Examination of the role of PET scan in assessing the response of breast cancer to chemotherapy especially in stage II and stage III patients will be done Up to three PET scans within one year may be performed Findings by PET scan will be correlated both with those of concurrent imaging techniques x-ray CT scan MRI bone scan or mammogram and with histologic biochemical and flow cytometric information on the tumor and with findings in subsequent surgical specimens Changes in tumor glucose metabolism with treatment will be assessed by PET imaging studies and by biochemical methods when possible
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 94-C-0151 | None | None | None |